Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
At a glance
- Drugs AMXT-1501 (Primary) ; Eflornithine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Aminex Therapeutics
- 20 Jun 2018 According to an Aminex Therapeutics media release, the company has received clearance from the US FDA to initiate this trial and the first patient has been dosed on 12 June 2018.
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.
- 28 May 2018 New trial record